Drugs/Approval·openFDA

Varibar Thin Honey — E-Z-EM Canada Inc drug label update

LowPublished May 15, 2026· AI-analyzed May 16, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

E-Z-EM Canada Inc updated the drug label for Varibar Thin Honey, a radiopaque contrast agent used in modified barium swallow examinations. The update clarifies its indication for evaluating oral and pharyngeal function and morphology in both adult and pediatric patients.

Who it affects

This update affects E-Z-EM Canada Inc, healthcare providers performing modified barium swallow examinations, and regulatory professionals managing contrast agent labeling.

Why it matters

The explicit inclusion of both adult and pediatric populations in the Indications and Usage section provides regulatory clarity for clinical applications across age groups. This update likely streamlines compliance for facilities using this specific barium sulfate formulation for swallow studies by aligning the label with current clinical practice standards for morphology and function evaluation.

Practical takeaway

Regulatory and clinical teams should verify that internal protocols and labeling for modified barium swallow examinations reflect the specific indication for both adult and pediatric populations. Quality systems should ensure that the updated Indications and Usage section is integrated into current product documentation.

FDA source material

Varibar Thin Honey (E-Z-EM Canada Inc). 1 INDICATIONS AND USAGE VARIBAR THIN HONEY is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. VARIBAR THIN HONEY is a radiopaque contrast agent indicated for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients ( 1 )

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.